Literature DB >> 17611707

Low-dose oral methotrexate for the management of childhood Cogan's syndrome: a case report.

Yuzaburo Inoue1, Takuya Tomemori2, Shuichi Suzuki3, Takayasu Arima3, Minako Tomiita3, Naoki Shimojo3, Yoichi Kohno3.   

Abstract

Cogan's syndrome is a rare inflammatory disease characterized by nonsyphilitic ocular interstitial keratitis associated with hearing loss and vestibular impairment. Although systemic corticosteroids are usually used as the standard therapy, hearing ability in most cases gradually deteriorates. We, herein, describe a patient with childhood Cogan's syndrome who was treated with low-dose oral methotrexate, which successfully helped to taper the doses of the systemic corticosteroids. The serum levels of the complements were good markers for the disease activity in this patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17611707     DOI: 10.1007/s10067-007-0686-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  11 in total

1.  Severe keratopathy in paediatric Cogan's syndrome.

Authors:  H Martínez-Osorio; G Fuentes-Páez; M Calonge
Journal:  Rheumatology (Oxford)       Date:  2006-09-14       Impact factor: 7.580

2.  Open trial of methotrexate as treatment for autoimmune hearing loss.

Authors:  E L Matteson; D A Fabry; G W Facer; C W Beatty; C L Driscoll; S E Strome; T J McDonald
Journal:  Arthritis Rheum       Date:  2001-04

3.  Efficacy of methotrexate in Cogan's syndrome.

Authors:  L Riente; E Taglione; S Berrettini
Journal:  J Rheumatol       Date:  1996-10       Impact factor: 4.666

4.  Cochleovestibular impairment in pediatric Cogan's syndrome.

Authors:  Issa C Ndiaye; Simon J Rassi; Sylvette R Wiener-Vacher
Journal:  Pediatrics       Date:  2002-02       Impact factor: 7.124

5.  Methotrexate as a steroid-sparing agent in Cogan's syndrome: comment on the concise communication by Richardson.

Authors:  J Pouchot; P Vinceneux; D Bouccara; O Sterkers; B Bodelet
Journal:  Arthritis Rheum       Date:  1995-09

6.  Lack of response to corticosteroids and pulse cyclophosphamide therapy in Cogan's syndrome.

Authors:  G Vaiopoulos; P P Sfikakis; B Skoumas; E Kavouklis; E Doukas; P Kaklamanis
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

7.  Methotrexate therapy for hearing loss in Cogan's syndrome.

Authors:  B Richardson
Journal:  Arthritis Rheum       Date:  1994-10

8.  Cogan syndrome: studies in thirteen patients, long-term follow-up, and a review of the literature.

Authors:  B F Haynes; M I Kaiser-Kupfer; P Mason; A S Fauci
Journal:  Medicine (Baltimore)       Date:  1980-11       Impact factor: 1.889

Review 9.  Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and nonrheumatic disorders.

Authors:  B H Singsen; R Goldbach-Mansky
Journal:  Rheum Dis Clin North Am       Date:  1997-11       Impact factor: 2.670

Review 10.  Typical and atypical Cogan's syndrome: 32 cases and review of the literature.

Authors:  A Grasland; J Pouchot; E Hachulla; O Blétry; T Papo; P Vinceneux
Journal:  Rheumatology (Oxford)       Date:  2004-05-18       Impact factor: 7.580

View more
  1 in total

Review 1.  Optimal management of Cogan's syndrome: a multidisciplinary approach.

Authors:  Vittorio D'Aguanno; Massimo Ralli; Marco de Vincentiis; Antonio Greco
Journal:  J Multidiscip Healthc       Date:  2017-12-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.